MedTrace Logo

Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy

NCT03709134 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-01-20

No results posted yet for this study

Summary

The primary aim of the study is to identify genomic markers (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), transcriptomic markers) as biomarkers of response to neoadjuvant chemotherapy (NAC) among patients with invasive breast cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

Genomic Markers (CTC/ctDNA)

This is a non-interventional study.

Sponsors & Collaborators

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Katarzyna J Jerzak, MD, MSc, FRCPC · Sunnybrook Health Sciences Centre

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2022-09-01
Completion
2022-09-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03709134 on ClinicalTrials.gov